Koasteam, Approval for Clinical Trial Phase 3 Protocol Amendment of Neuronata-RJ

[Asia Economy Reporter Oh Ju-yeon] Corestem announced on the 27th that it has received approval from the Ministry of Food and Drug Safety for changes to the domestic Phase 3 clinical trial plan of Neuronata-AL injection.

The company stated, "We have received approval for changes to the clinical trial plan, including the administration period, efficacy evaluation variables, and the number of subjects."

The target disease is amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).